Instituto de Investigación Sanitaria, ALS Unit

University Hospital 12 de Octubre

The ALS Unit at the Hospital 12 de Octubre in Madrid is one of the 4 ALS Units in the capital district of Spain. It is the only one in the whole country which includes a research laboratory.

University Hospital 12 de Octubre

Our principal aims are to study the genetics of the Spanish ALS population, to discover new prognostic and diagnostic biomarkers, and to develop preclinical and clinical assays.

Contact
Location
University Hospital 12 de Octubre, Avenida de Córdoba, Madrid, Spain
Contact

Our Specialists

Jesús Esteban Pérez

Principal investigator

Dr. Jesús Esteban Pérez is Principal investigator in University Hospital 12 de […]

Jesús Esteban Pérez
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more